PURPOSE: There are several recent articles in medical literature conclude that stress is associated with the change of immunity, but no one dealing with sarcoidosis. The focus of this study is to examine the influence of negative life events in patients with sarcoidosis and their coincidence with the course of the disease and the possible outcome, as well as with the time of disease relapse.
METHODS: We analyzed 111 biopsy positive sarcoidosis patients (pts): 86 female and 25 male, the mean age 43. 73 years. SD 10.9. Follow up period 10 years. In order to measure the life events stress influence we used the Life Events Scale (also known as the Holmes & Rahe Social Readjustment Rating Scale). The life events are ranked in order from the most stressful (death of spouse -counted as 100) to the least stressful (minor violations of the law -counted as 11). The Life Events Scale (LES) has 43 items. The overall score is ranging from 0–149 low susceptibility to stress related disease; 150–299 medium susceptibility to stress related disease, and 300 and beyond high susceptibility to stress related disease.
RESULTS: LES score < 150 had 40, 5% of the analyzed patients. Total LES score ranging from 150–299 was found in 41, 5% of our patients.18% from the analyzed group show high susceptibility for stress related disease with the total LES score of 300 and higher. The most interesting finding appeared that the majority of our patients (60pts) 54% with the LES scores of 200 and higher were patients with chronic sarcoidosis lasting for more than 5 years with worsening disease course during the mentioned stress events.
CONCLUSION: The examination performed in sarcoidosis pts shows the interactions between behavioral and immune processes providing an insight into means by which psychosocial stressors may influence the development and expression of this inflammatory disease.
CLINICAL IMPLICATIONS: Literature emphases severe asthma attacks and disease worsening to be stress related. The same seems to happen with granulomatous inflammation in sarcoidosis patients.
DISCLOSURE: Violeta Vucinic, No Financial Disclosure Information; No Product/Research Disclosure Information